Spains Pharmamar Says Covid-19 Treatment Drug Shows Clinical Efficacy In Trials
Spain'S Pharmamar Said On Wednesday The First Trials Of Its Aplidin Drug On Hospitalised Patients With Moderate Covid-19 Showed Clinical Effects And Met Safety Standards.The Results Of These First Tests Allowed The Company To Secure Spanish Regulatory Approval To Carry Out A Late-Stage Trial On Patients In A Phase Iii Trial Last Month."The Company Has Decided To Share This Data, Which Demonstrates The Therapeutic Potential Of This Drug, With The Entire Scientific And Medical Communities, Along With Patients," Pharmamar Said In A Statement. Britain'S Medical Regulator Authorised The Trials Two Months Ago After The Journal Science Published A Paper Showing The Drug Had Encouraging Antiviral Results During Vitro Testing.Aplidin Is A Drug Developed By Pharmamar Originally To Treat Cancer But Has An Effect As An Antiviral.Shares Of Pharmamar Were Up 1% To 80.70 Euros ($98.75) In Early Trading.

Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!